Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2017

  • ID: 4426925
  • Report
  • 98 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Asana BioSciences LLC
  • Clevexel Pharma SAS
  • Genosco Inc
  • GlaxoSmithKline Plc
  • Japan Tobacco Inc
  • MORE
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2017

Summary

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 27 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 3, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Hematological Disorders, Ophthalmology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Rheumatoid Arthritis, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Autoimmune Disorders, Peripheral T-Cell Lymphomas (PTCL), Allergic Conjunctivitis, Asthma, Atopic Dermatitis, B-Cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Cutaneous Lupus Erythematosus, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Ulcerative Colitis, Acquired (Autoimmune) Hemolytic Anemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Allergies, Alzheimer's Disease, Anaphylactic Shock, Arthritis, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blood Cancer, Chronic Urticaria Or Hives, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glomerulonephritis, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Inflammation, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye), Kidney Transplant Rejection, Lupus Nephritis, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Myelofibrosis, Non-Small Cell Lung Cancer, Peritoneal Cancer, Post-Transplant Lymphoproliferative Disorder, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sicca Syndrome (Sjogren), Solid Tumor and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics.
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Asana BioSciences LLC
  • Clevexel Pharma SAS
  • Genosco Inc
  • GlaxoSmithKline Plc
  • Japan Tobacco Inc
  • MORE
Introduction

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development

AB Science SA

Almirall SA

Archer Pharmaceuticals Inc

Asana BioSciences LLC

Beijing Hanmi Pharmaceutical Co Ltd

Celgene Corp

Clevexel Pharma SAS

Fujifilm Corp

Genosco Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Hutchison MediPharma Ltd

Japan Tobacco Inc

Levolta Pharmaceuticals Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Portola Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

TopiVert Ltd

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles

AB-8779 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-509 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0074 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entospletinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FF-10102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fostamatinib disodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-492429 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9876 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2646264 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTE-852 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAS-189386 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilvadipine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRT-2761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKIO-703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SYK and JAK for Autoimmune Disorders and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SYK for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-659 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1630 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1890 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Nov 01, 2017: Takeda to Present Data On TAK-659 During 59th ASH Annual Meeting

Oct 03, 2017: Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia Phase 2 Study

Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP

Jul 19, 2017: Onyx helps accelerate TopiVert's compound to clinic

Jul 19, 2017: TopiVert Provides Update on TOP1630

Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL

Jun 22, 2017: Rigel Announces Oral Presentation of TAVALISSE Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress

Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP

Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma

May 30, 2017: Asana BioSciences Initiates Phase 2 Evaluation of ASN002, a Novel SYK/JAK Inhibitor, in NHL, CLL and MF

May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association

May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma

Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States

Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP

Mar 27, 2017: Asana BioSciences To Present New Data on ASN002 at AACR 2017

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AB Science SA, H2 2017

Pipeline by Almirall SA, H2 2017

Pipeline by Archer Pharmaceuticals Inc, H2 2017

Pipeline by Asana BioSciences LLC, H2 2017

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017

Pipeline by Celgene Corp, H2 2017

Pipeline by Clevexel Pharma SAS, H2 2017

Pipeline by Fujifilm Corp, H2 2017

Pipeline by Genosco Inc, H2 2017

Pipeline by Gilead Sciences Inc, H2 2017

Pipeline by GlaxoSmithKline Plc, H2 2017

Pipeline by Hutchison MediPharma Ltd, H2 2017

Pipeline by Japan Tobacco Inc, H2 2017

Pipeline by Levolta Pharmaceuticals Inc, H2 2017

Pipeline by Merck KGaA, H2 2017

Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Pipeline by Portola Pharmaceuticals Inc, H2 2017

Pipeline by Rigel Pharmaceuticals Inc, H2 2017

Pipeline by TopiVert Ltd, H2 2017

Dormant Products, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • Almirall SA
  • Archer Pharmaceuticals Inc
  • Asana BioSciences LLC
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Celgene Corp
  • Clevexel Pharma SAS
  • Fujifilm Corp
  • Genosco Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Hutchison MediPharma Ltd
  • Japan Tobacco Inc
  • Levolta Pharmaceuticals Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Portola Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • TopiVert Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll